Novo Nordisk CEO: Outcomes-Based Contracts For Diabetes ‘Problematic’
Executive Summary
In interview with “The Pink Sheet,” Lars Sorensen discusses the pricing and rebating environment for diabetes drugs and the company’s attitude toward exclusionary formularies.